Quantitative PCR as a marker for preemptive therapy and its role in therapeutic control in Trypanosoma cruzi/HIV coinfection.
Vera Lúcia Teixeira de FreitasChristina Terra Gallafrio NovaesAna Marli Christovam SartoriNoemia Barbosa CarvalhoSheila Cristina Vicente da SilvaÉrika Shimoda NakanishiFernando SalvadorCleudson Nery de CastroRita Cristina BezerraElizabeth Visone Nunes WestphalenCaroline Medeji Ramos de OliveiraFelipe Delatorre BusserYeh-Li HoRenata BuccheriCarolina BonillaMaria Aparecida Shikanai YasudaPublished in: PLoS neglected tropical diseases (2024)
We recommend qPCR prospective monitoring of T. cruzi parasitemia in HIV+ coinfected patients and point out the value of pre-emptive therapy for those with high parasitemia. In parallel, early antiretroviral therapy introduction is advisable, aiming at viral load control, immune response restoration, and increasing survival. We also suggest an early antiparasitic treatment for all coinfected patients, followed by effectiveness analysis alongside antiretroviral therapy.
Keyphrases
- antiretroviral therapy
- hiv infected
- hiv positive
- end stage renal disease
- human immunodeficiency virus
- hiv aids
- immune response
- hiv infected patients
- chronic kidney disease
- ejection fraction
- newly diagnosed
- randomized controlled trial
- hepatitis c virus
- prognostic factors
- high resolution
- peritoneal dialysis
- stem cells
- hiv testing
- men who have sex with men
- trypanosoma cruzi
- patient reported outcomes
- inflammatory response
- mass spectrometry
- patient reported
- data analysis